TrialClinical rheumatology2014

Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years.

Daniel J Kingsbury et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.